Sector News

Novartis to close Puerto Rico plant by 2019, move some operations to Lincoln plant

January 19, 2015
Life sciences
(AP) — Novartis AG is closing its manufacturing plant in Puerto Rico as part of a major overhaul of its business, the company said in a statement Friday.
 
The Switzerland-based company said the shutdown of its Humacao plant will conclude in early 2019. Some 270 employees will be laid off.
 
Novartis said it will transfer some manufacturing and packaging operations to companies including Eli Lilly & Co. Some operations also will be transferred to Novartis’ manufacturing plant in Lincoln, Nebraska.
 
Puerto Rico’s Industrial Development Company said it would seek to sell the plant to a local company or to one taking over some of Novartis’ operations.
 
The U.S. territory is still considered one of the world’s leading centers for pharmaceutical manufacturing, but the sector has been shrinking. The government has been offering incentives for manufacturing plants to expand and is pushing to diversify its manufacturing base by seeking aerospace and information technology companies.
 
Novartis’ Humacao plant opened in 1975.

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach